These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16076946)

  • 1. Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome.
    Glintborg D; Støving RK; Hagen C; Hermann AP; Frystyk J; Veldhuis JD; Flyvbjerg A; Andersen M
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5605-12. PubMed ID: 16076946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome.
    Glintborg D; Hermann AP; Hagen C; Jensen LT; Frystyk J; Bennett P; Flyvbjerg A; Andersen M
    Fertil Steril; 2009 Mar; 91(3):842-50. PubMed ID: 18402944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
    Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
    Ciaraldi TP; Aroda V; Mudaliar SR; Henry RR
    Metabolism; 2013 Nov; 62(11):1587-96. PubMed ID: 23958241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial.
    Glintborg D; Andersen M; Hagen C; Heickendorff L; Hermann AP
    J Clin Endocrinol Metab; 2008 May; 93(5):1696-701. PubMed ID: 18285411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
    Koo YA; Shin SY; Yoon BK; Choi D
    Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
    Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
    Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial.
    Aroda VR; Ciaraldi TP; Burke P; Mudaliar S; Clopton P; Phillips S; Chang RJ; Henry RR
    J Clin Endocrinol Metab; 2009 Feb; 94(2):469-76. PubMed ID: 18984667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment.
    Glintborg D; Højlund K; Andersen M; Henriksen JE; Beck-Nielsen H; Handberg A
    Diabetes Care; 2008 Feb; 31(2):328-34. PubMed ID: 18000176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
    Svensson J; Lönn L; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Boseaus I; Sjöström L; Bengtsson BA
    J Clin Endocrinol Metab; 1998 Feb; 83(2):362-9. PubMed ID: 9467542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Free carnitine and acylcarnitines in obese patients with polycystic ovary syndrome and effects of pioglitazone treatment.
    Vigerust NF; Bohov P; Bjørndal B; Seifert R; Nygård O; Svardal A; Glintborg D; Berge RK; Gaster M
    Fertil Steril; 2012 Dec; 98(6):1620-6.e1. PubMed ID: 22999793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome.
    Glintborg D; Hermann AP; Andersen M; Hagen C; Beck-Nielsen H; Veldhuis JD; Henriksen JE
    Fertil Steril; 2006 Aug; 86(2):385-97. PubMed ID: 16782094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.
    Corpas E; Harman SM; Piñeyro MA; Roberson R; Blackman MR
    J Clin Endocrinol Metab; 1992 Aug; 75(2):530-5. PubMed ID: 1379256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low amplitude and disorderly spontaneous growth hormone release in obese women with or without polycystic ovary syndrome.
    Van Dam EW; Roelfsema F; Helmerhorst FH; Frölich M; Meinders AE; Veldhuis JD; Pijl H
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4225-30. PubMed ID: 12213875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amplified and orderly growth hormone secretion characterizes lean adolescents with polycystic ovary syndrome.
    Garcia-Rudaz MC; Ropelato MG; Escobar ME; Veldhuis JD; Barontini M
    Eur J Endocrinol; 2002 Aug; 147(2):207-16. PubMed ID: 12153742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone secretion is impaired but not related to insulin sensitivity in non-obese patients with polycystic ovary syndrome.
    de Boer JA; Lambalk CB; Hendriks HH; van Aken C; van der Veen EA; Schoemaker J
    Hum Reprod; 2004 Mar; 19(3):504-9. PubMed ID: 14998943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid hormones and response to pioglitazone treatment.
    Aigner E; Bachofner N; Klein K; De Geyter C; Hohla F; Patsch W; Datz C
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1229-35. PubMed ID: 19158194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome.
    Orio F; Palomba S; Colao A; Russo T; Dentico C; Tauchmanovà L; Savastano S; Nappi C; Sultan C; Zullo F; Lombardi G
    J Endocrinol Invest; 2003 Feb; 26(2):117-22. PubMed ID: 12739737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysfunction of the growth hormone/insulin-like growth factor-I axis in women with polycystic ovarian syndrome.
    Piaditis GP; Kounadi TG; Rangou DB; Trovas GP; Kaklas NA; Tzonou AJ; Chlouverakis CS
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):635-40. PubMed ID: 7634505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.